HPV16/18 E6/E7 DNA疫苗在宫颈癌放化疗后安全性与耐受性的1期试验
这项1期试验评估了放化疗后针对HPV16/18 E6/E7的治疗性DNA疫苗MEDI0457在宫颈癌患者中的安全性与耐受性。10例患者接受4次免疫接种,治疗相关不良事件均为1级,主要与注射部位相关;8/10例产生细胞或体液免疫应答,所有患者宫颈活检HPV DNA清除。结论认为该疫苗放化疗后安全且耐受良好,支持进一步研究肿瘤特异性疫苗与放疗联合。
要点
- 放化疗后接种MEDI0457治疗相关不良事件均为1级,主要与注射部位相关。
- 8/10例患者产生抗HPV细胞或体液免疫应答,6/10例产生抗体应答,6/10例产生IFNγ T细胞应答。
- 完成放化疗和疫苗接种后,所有患者宫颈活检可检测HPV DNA均清除。
核心结论
- 放化疗后辅助接种MEDI0457在局部晚期或复发宫颈癌患者中安全且耐受良好,支持进一步研究肿瘤特异性疫苗与放疗联合。
研究设计与样本
- 1期试验纳入10例新诊断IB1-IVA期(队列1,n=7)或持续/复发(队列2,n=3)宫颈癌患者,放化疗后2至4周开始每4周接种4次MEDI0457。
- MEDI0457(INO-3112)为靶向HPV-16/18 E6和E7的DNA疫苗,与IL-12质粒共注射后使用CELLECTRA 5P装置电穿孔。
- 主要终点为不良事件发生率和注射部位反应发生率。
主要发现
- 10例患者中HPV16阳性7例、HPV18阳性3例,治疗相关不良事件均为1级,主要与注射部位相关。
- 8/10例患者在放化疗和疫苗接种后可检测到针对HPV抗原的细胞或体液免疫应答。
- 6/10例患者产生抗HPV抗体应答,6/10例患者产生IFNγ-producing T细胞应答。
- 完成放化疗和疫苗接种时,宫颈活检标本可检测到CD8+ T细胞,并观察到PD-1+CD8+、PD-L1+CD8+和PD-L1+CD68+亚群减少。
- 完成放化疗和疫苗接种后,所有患者宫颈活检中可检测的HPV DNA均清除。
临床怎么用
- 对于局部晚期或复发宫颈癌患者,放化疗后接种靶向HPV16/18 E6/E7的DNA疫苗可能安全且耐受良好,并诱导免疫应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study assessed the safety and tolerability of therapeutic immunization against the human papillomavirus (HPV) viral oncoproteins E6 and E7 in patients with cervical cancer after chemoradiation. METHODS AND MATERIALS: MEDI0457 (INO-3112) is a DNA-based vaccine targeting E6 and E7 of HPV-16/18 that is coinjected with an IL-12 plasmid followed by electroporation with the CELLECTRA 5P device. At 2 to 4 weeks after chemoradiation, patients with newly diagnosed stage IB1-IVA (cohort 1) or persistent/recurrent (cohort 2) cervical cancers were treated with 4 immunizations of MEDI0457 every 4 weeks. The primary endpoints were incidence of adverse events and injection site reactions. Immune responses against HPV antigens were measured by ELISpot for interferon-γ (IFNγ), enzyme-linked immunosorbent assay for antibody responses and multiplexed immunofluorescence for immune cells in cervical biopsy specimens. RESULTS: Ten patients (cohort 1, n = 7; cohort 2, n = 3) with HPV16 (n = 7) or HPV18 (n = 3) cervical cancers received MEDI0457 after chemoradiation. Treatment-related adverse events were all grade 1, primarily related to the injection site. Eight of 10 patients had detectable cellular or humoral immune responses against HPV antigens after chemoradiation and vaccination: 6 of 10 patients generated anti-HPV antibody responses and 6 of 10 patients generated IFNγ-producing T cell responses. At the completion of chemoradiation and vaccination, cervical biopsy specimens had detectable CD8+ T cells and decreased PD-1+CD8+, PD-L1+CD8+, and PD-L1+CD68+ subpopulations. All patients cleared detectable HPV DNA in cervical biopsies by completion of chemoradiation and vaccination. CONCLUSIONS: Adjuvant MEDI0457 is safe and well tolerated after chemoradiation for locally advanced or recurrent cervical cancers, supporting further investigation into combining tumor-specific vaccines with radiation therapy.
引用
- Hasan Y, Furtado L, Tergas A, et al. A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 32151670. doi:10.1016/j.ijrobp.2020.02.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。